公开(公告)号：US20230151109A1

公开(公告)日：2023-05-18

申请号：US17929031

申请日：2020-02-13

Applicant: UCB BIOPHARMA SRL

Inventor： David Alan COOK ,  Helen Margaret FINNEY ,  Stephen Edward RAPECKI

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2896 ,  C07K16/2878 ,  A61P35/00 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/75

Abstract: The present invention relates to multispecific antibodies against a novel targets' combination of CD9 and another antigen, and their use in the treatment of cancer and infectious diseases.

公开(公告)号：US20230096030A1

公开(公告)日：2023-03-30

申请号：US17929029

申请日：2020-02-13

Applicant: UCB BIOPHARMA SRL

Inventor： David Alan COOK ,  Helen Margaret FINNEY ,  Stephen Edward RAPECKI

IPC: C07K16/28

Abstract: The present invention relates to multispecific antibodies against a novel targets' combination of CD7 and CD9, and their use in the treatment of cancer and infectious diseases.

公开(公告)号：US20230151108A1

公开(公告)日：2023-05-18

申请号：US17929026

申请日：2020-02-13

Applicant: UCB BIOPHARMA SRL

Inventor： David Alan COOK ,  Helen Margaret FINNEY ,  Stephen Edward RAPECKI

IPC: C07K16/28 ,  C07K14/765 ,  A61P35/00

CPC classification number: C07K16/2896 ,  C07K16/2878 ,  C07K14/765 ,  A61P35/00 ,  A61K2039/505

Abstract: The present invention relates to multispecific antibodies against a novel targets' combination of CD137 and CD9, and their use in the treatment of cancer and infectious diseases.

公开(公告)号：US20230125234A1

公开(公告)日：2023-04-27

申请号：US17929032

申请日：2020-02-13

Applicant: UCB BIOPHARMA SRL

Inventor： David Alan COOK ,  Helen Margaret FINNEY ,  Stephen Edward RAPECKI

IPC: C07K16/28 ,  A61P35/00

Abstract: The present disclosure relates to a bispecific anti CD44/anti CTLA4 antibody. The antibody construct has defined CDRs and variable chains sequences. The bispecific antibodies has improved activity on CDS and CD4 T cells compared to known antibodies.

公开(公告)号：US20230374148A1

公开(公告)日：2023-11-23

申请号：US18248651

申请日：2021-10-14

Applicant: UCB BIOPHARMA SRL

Inventor： Stephen Edward RAPECKI ,  Ralph ADAMS ,  David Paul HUMPHREYS ,  Helen Margaret FINNEY ,  Rosemary Frances BITHELL

IPC: C07K16/28 ,  C07K16/18 ,  A61P35/00 ,  A61P35/02

CPC classification number: C07K16/289 ,  C07K16/18 ,  A61P35/00 ,  A61P35/02 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/72 ,  C07K2317/55 ,  C07K2317/92 ,  C07K2317/35

Abstract: The present invention provides binding molecule or molecules that are able to multimerise CD45 to induce cell death of a cell expressing CD45 without also inducing significant cytokine release. For example, the invention provides antibodies against CD45, wherein the antibodies comprise at least two different paratopes each specific for a different epitope of CD45. The antibodies may be used to cross-link CD45 on the surface of cells. The antibodies may be used in a variety of therapeutic ways including to deplete cells, for example prior to cell transplantation.

公开(公告)号：US20230192900A1

公开(公告)日：2023-06-22

申请号：US17929028

申请日：2020-02-13

Applicant: UCB BIOPHARMA SRL

Inventor： David Alan COOK ,  Helen Margaret FINNEY ,  Stephen Edward RAPECKI

IPC: C07K16/46

CPC classification number: C07K16/468 ,  C07K2317/31 ,  C07K2317/24 ,  C07K2317/94 ,  C07K2317/565

Abstract: The present invention relates to multispecific antibodies against a novel targets' combination of HVEM and CD9, and their use in the treatment of cancer and infectious diseases.